Teniposide Side Effects
Some side effects of teniposide may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to teniposide: intravenous solution
Get emergency medical help if you have any of these signs of an allergic reaction while taking teniposide: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
fever, chills, itching, body aches, flu symptoms, sores in your mouth and throat;
easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating;
fast or pounding heartbeats, wheezing, chest tightness, trouble breathing;
severe headache, buzzing in your ears, anxiety, confusion, chest pain, uneven heartbeats;
pain, burning, irritation, or skin changes where the injection was given;
feeling like you might pass out; or
severe nausea and vomiting.
Less serious side effects of teniposide may include:
drowsiness, dizziness, feeling tired or weak;
mild nausea, stomach pain, loss of appetite;
temporary hair loss; or
mild skin rash.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to teniposide: intravenous solution
Hematologic side effects have included bone marrow suppression which is the most significant toxicity associated with teniposide therapy. Hematologic effects including neutropenia (less than 2,000 ANC/mcL), leukopenia (less than 3,000 WBC/mcL), anemia (88%), thrombocytopenia (less than 100,000 platelets/mcL) (85%), myelosuppression (unspecified) (75%), and bleeding (5%) have been reported. Sepsis, sometimes fatal, may be a consequence of severe myelosuppression.
Hypersensitivity side effects (5%) have been reported. These have included some potentially life threatening hypersensitivity reactions with anaphylaxis-like symptoms.
The hypersensitivity reaction may include chills, fever, urticaria, tachycardia, bronchospasm, dyspnea, hypertension or hypotension, and facial flushing. Treatment for a severe hypersensitivity reaction include prompt use of antihistamines, corticosteroids, epinephrine, intravenous fluids, and other supportive measures.
One analysis of hypersensitivity reactions to teniposide concluded that the frequency of the reactions is substantially higher in patients with neuroblastoma and brain tumors.
Cardiovascular side effects including hypotension/cardiovascular (2%) have been reported. One episode of sudden death attributable to probable arrhythmia and intractable hypotension has also been reported.
Oncologic side effects include one report of a relative risk of developing secondary acute nonlymphocytic leukemia approximately twelve times that of patients treated with less intensive schedules.
The patients in the report were children with acute lymphoblastic leukemia in remission who received teniposide plus other chemotherapeutic agents at weekly or twice weekly doses.
Compounds with similar mechanisms of action and mutagenicity profiles have been carcinogenic. Teniposide should be considered to be a potential carcinogen. Teniposide has been shown to be mutagenic in various bacterial and mammalian genetic toxicity tests.
Gastrointestinal side effects including mucositis (76%), diarrhea (33%), and nausea/vomiting (29%) have been reported.
Immunologic side effects including infection (12%) have been reported.
Alopecia, which sometimes progressed to total baldness, was usually reversible.
Dermatologic side effects including alopecia (9%) and rash (3%) have been reported.
General side effects including fever and asthenia have been reported.
Nervous system side effects have included headache, confusion, neurotoxicity and, at investigational high doses, acute CNS depression has been reported.
Other side effects have included three case reports of somnolence, hypotension, and metabolic acidosis which have been reported with teniposide doses at three to five times the standard dose.
More teniposide resources
- teniposide Concise Consumer Information (Cerner Multum)
- teniposide MedFacts Consumer Leaflet (Wolters Kluwer)
- teniposide Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information
- Teniposide Professional Patient Advice (Wolters Kluwer)
- Teniposide Monograph (AHFS DI)
- Vumon Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.